Modern Approaches to Diagnosis and Treatment of Essential Thrombocythemia: Literature Review and Own Experience

KM Abdulkadyrov, VA Shuvaev, IS Martynkevich

Russian Scientific Research Institute of Hematology and Transfusiology, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024

For correspondence: Vasilii Anatol’evich Shuvaev, PhD, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024; Tel. +7 (921) 636-54-72; e-mail:

For citation: Abdulkadyrov KM, Shuvaev VA, Martynkevich IS. Modern Approaches to Diagnosis and Treatment of Essential Thrombocythemia: Literature Review and Own Experience. Clinical oncohematology. 2015;8(3):235–47 (In Russ).


Objective. The aim of our study was to present literature data and own experience about epidemiology, terminology, etiology and pathogenesis of еssential thrombocythemia.

Methods. Molecular and genetic aspects of the disease pathogenesis and its clinical manifestations are described. The article dwells on issues related to diagnostic criteria, differential diagnosis and classification of essential thrombocythemia. Results of molecular genetic and cytogenetic studies, major causes of thrombotic complications, and methods of their prevention and treatment are presented. Treatment options and monitoring, as well as evaluation of the treatment effectiveness get considerable coverage. Literature review and analysis of diagnostic and treatment results of 218 essential thrombocythemia patients are presented: of them 161 were females, 57 were males, the gender ratio was 2.8:1, and the median age was 57.2 (varied from 18.3 to 89.3 years). Chromosomal aberrations were found in 7 (9.3 %) of 65 patients who had undergone cytogenetic testing. A JAK2V617F mutation was identified in 79 (58.1 %) of 136 patients, and a MPL gene mutation in 1 (2.3 %) of 44 patients.

Results. The overall 10 year survival rate of 218 essential thrombocythemia patients was 83.9 %. Progression in the form of secondary post-essential thrombocythemia myelofibrosis was registered in 13 (6 %) patients. The treatment included hydroxyurea (n = 132), interferons-a (n = 37), anagrelide (n = 10), and acetylsalicylic acid (n = 54). The mortality rate over the whole 10 year observation period was 16.1 % (n = 35).

Conclusion. Timely and early diagnosis of essential thrombocythemia, thrombosis risk-adapted management and adequate follow-up with platelet count monitoring are cornerstones for preservation of patient’s duration and quality of life.

Keywords: essential thrombocythemia, Janus kinase 2 (JAK2) gene mutation, thrombotic complications risk, diagnostic and treatment algorithm.

Received: January 14, 2015

Accepted: May 26, 2015

Read in PDF (RUS)pdficon


  1. Izaguirre-Avila R, Penia-Diaz A, De la Barinagarrementeria-Aldatz F, et al. Effect of Clopidogrel on Platelet Aggregation and Plasma Concentration of Fibrinogen in Subjects with Cerebral or Coronary Atherosclerotic Disease. Clin Applied Thromb Hemost. 2002;8(2):169–77. doi: 10.1177/107602960200800214.
  2. Абдулкадыров К.М. Клиническая гематология: справочник. СПб.: Питер Принт, 2006. 447 с.
    [Abdulkadyrov KM. Klinicheskaya gematologiya: spravochnik. (Clinical hematology: textbook.) Saint Petersburg: Piter Print Publ.; 2006. 447 p. (In Russ)]
  3. Воробьев А.И. Руководство по гематологии. М.: Ньюдиамед, 2003. Ч. 3. С. 9–15.
    [Vorob’ev AI. Rukovodstvo po gematoligii. (Guidelines in Hematology.) Moscow: NewDiamed Publ.; 2003. Vol. 3. pp. 9–15. (In Russ)]
  4. Абдулкадыров К.М., Шуваев В.А. Эссенциальная тромбоцитемия: современные представления о диагностике и лечении. СПб., 2014. 49 с.
    [Abdulkadyrov KM, Shuvaev VA. Essentialnaya trombocytemia: sovremennye predstavleniya o diagnostike i lechenii. (Essential thrombocythemia: modern concepts about diagnostics and treatment.) Saint Petersburg; 2014. 49 p. (In Russ)]
  5. Epstein E, Goedel A. Hammorhagische thrombocythamie bei vascularer schrumpfmilz. Virchow Arch. (Pathol. Anat.) 1934;292(2):233–48. doi: 10.1007/bf01891529.
  6. Dameshek W. Editorial: Some Speculations on the Myeloproliferative Syndromes. Blood. 1951;6(4):372–5.
  7. Mesa RA, Silverstein MN, Jacobsen SJ, et al. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted county study, 1976–1995. Am J Hematol. 1999;61(1):10–5. doi: 10.1002/(sici)1096-8652(199905)61:1<10::aid-ajh3>;2-i.
  8. Tefferi A, Solberg LA Jr, Silverstein MN. A clinical update in polycythemia vera and essential thrombocythemia. Am J Med. 2000;109(2):141–9. doi: 10.1016/s0002-9343(00)00449-6.
  9. Shuvaev VA, Abdulkadyrova AS, Martynkevich IS, et al. Essential thrombocythemia – population analysis, a single center 10-years’ experience. ELN Inform Letter. October 2013:21.
  10. Beer PA, Erber WN, Campbell PJ, et al. How I treat essential thrombocythemia. Blood. 2011;117(5):1472–82. doi: 10.1182/blood-2010-08-270033.
  11. Levine RL, Heaney M. New advances in the pathogenesis and therapy of essential thrombocythemia. Hematology Am Soc Hematol Educ Program. 2008(1):76–82. 10.1182/asheducation-2008.1.76.
  12. Vannucchi AM, Guglielmelli P. Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations. Haematologica. 2008;93(7):972–6. doi: 10.3324/haematol.13266.
  13. Tefferi A. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013;88(6):507–16. doi: 10.1002/ajh.23417.
  14. Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013;121(23):4778–81. doi: 10.1182/blood-2013-01-478891.
  15. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. N Engl J Med. 2013;369(25):2379–90. doi: 10.1056/nejmoa1311347.
  16. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2. N Engl J Med. 2013;369(25):2391–405. doi: 10.1056/nejmoa1312542.
  17. Hofmann SR, Lam AQ, Frank S, et al. Jak3-Independent Trafficking of the Common g Chain Receptor Subunit: Chaperone Function of Jaks Revisited. Mol Cell Biol. 2004;24(11):5039–49. doi: 10.1128/mcb.24.11.5039-5049.2004.
  18. Kamakura S, Oishi K, Yoshimatsu T, et al. Hes binding to STAT3 mediates crosstalk between Notch and JAK-STAT signalling. Nat Cell Biol. 2004;6(6):547–54. doi: 10.1038/ncb1138.
  19. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. The Lancet. 2005;366(9501):1945–53. doi: 10.1016/s0140-6736(05)67785-9.
  20. Levine RL, Heaney M. New Advances in the Pathogenesis and Therapy of Essential Thrombocythemia. ASH Educ Program Book. 2008:76–82. doi: 10.1182/asheducation-2008.1.76.
  21. Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia. 2014;28(7):1407–13. doi: 10.1038/leu.2014.35.
  22. Abe M, Suzuki K, Inagaki O, et al. A novel MPL point mutation resulting in thrombopoietin-independent activation. Leukemia. 2002;16(8):1500–6. doi: 10.1038/sj.leu.2402554.
  23. Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2013;123(10):1552–5. doi: 10.1182/blood-2013-11-538983.
  24. Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2013;123(10):1544–51. doi: 10.1182/blood-2013-11-539098.
  25. Kiladjian J-J, Rain J-D, Bernard J-F, et al. Long-Term Incidence of Hematological Evolution in Three French Prospective Studies of Hydroxyurea and Pipobroman in Polycythemia Vera and Essential Thrombocythemia. Semin Thromb Hemost. 2006;32(4):417–21. doi: 10.1055/s-2006-942762.
  26. Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol. 2003;74(1):26–31. doi: 10.1002/ajh.10375.
  27. Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93(11):1645–51. doi: 10.3324/haematol.13346.
  28. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117(10):755–61. doi: 10.1016/j.amjmed.2004.06.032.
  29. Alvarez-Larran A, Cervantes F, Bellosillo B, et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia. 2007;21(6):1218–23. doi: 10.1038/sj.leu.2404967.
  30. Campbell PJ, MacLean C, Beer PA, et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood. 2012;120(7):1409–11. doi: 10.1182/blood-2012-04-424911.
  31. Ruggeri M, Tosetto A, Frezzato M, et al. The Rate of Progression to Polycythemia Vera or Essential Thrombocythemia in Patients with Erythrocytosis or Thrombocytosis. Ann Intern Med. 2003;139(6):470–5. doi: 10.7326/0003-4819-139-6-200309160-00009.
  32. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol. 1997;34(1):29–39.
  33. Panani AD. Cytogenetic Findings in Untreated Patients with Essential Thrombocythemia. In Vivo. 2006;20(3):381–4.
  34. Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128–32.
  35. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092–7. doi: 10.1182/blood-2007-04-083501.
  36. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2007;22(1):14–22. doi: 10.1038/sj.leu.2404955.
  37. Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization – essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128–33. doi: 10.1182/blood-2012-07-444067.
  38. Jensen MK, De Nully B, Hasselbach OJ, et al. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol. 2000;65(2):132–9. doi: 10.1034/j.1600-0609.2000.90236.x.
  39. Michiels JJ, Van Genderen P, Lindemans JJ, et al. Erythromelalgic, Thrombotic and Hemorrhagic Manifestations in 50 Cases of Thrombocythemia. Leuk Lymphoma. 1996;22(s1):47–56. doi: 10.3109/10428199609074360.
  40. Alvarez-Larran, A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010;116(8):1205–10. doi: 10.1182/blood-2010-01-263319.
  41. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for Patients with Essential Thrombocythemia and a High Risk of Thrombosis. N Engl J Med. 1995;332(17):1132–7. doi: 10.1056/nejm199504273321704.
  42. Gisslinger H, Holowiecki J, Penka M, et al. Final Results of the ANAHYDRET-Study: Non-Inferiority of Anagrelide Compared to Hydroxyurea in Newly Diagnosed WHO-Essential Thrombocythemia Patients. Blood (ASH Annual Meeting Abstracts). 2008;112:661.
  43. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia. N Engl J Med. 2005;353(1):33–45. doi: 10.1056/nejmoa043800.
  44. Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol. 1997;34(1):17–23.
  45. Kiladjian JJ, Chomienne C, Fenaux P. Interferon-[alpha] therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia. 2008;22(11):1990–8. doi: 10.1038/leu.2008.280.
  46. Lengfelder E, Griesshammer M, Hehlmann R. Interferon-alpha in the Treatment of Essential Thrombocythemia. Leuk Lymphoma. 1996;22(Suppl 1):135–42. doi: 10.3109/10428199609074371.
  47. Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera. J Clin Oncol. 2009;27(32):5418–24. doi: 10.1200/jco.2009.23.6075.
  48. Quintas-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a. Blood. 2013;122(6):893–901. doi: 10.1182/blood-2012-07-442012.
  49. Cassinat B, Verger E, Kiladjian J-J. Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia. N Engl J Med. 2014;371(2):188–9. doi: 10.1056/nejmc1401255.
  50. Sacchi S, Tabilio A, Leoni P, et al. Interferon alpha-2b in the long-term treatment of essential thrombocythemia. Ann Hematol. 1991;63(4):206–9. doi: 10.1007/bf01703444.
  51. Langer C, Lengfelder E, Thiele J, et al. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. Haematologica. 2005;90(10):1333–8.
  52. Mascarenhas J, Mesa R, Prchal J, et al. Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials. Haematologica. 2014;99(6):945–9. doi: 10.3324/haematol.2014.106013.
  53. Alvarado Y, Cortes J, Verstovsek S, et al. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol. 2003;51(1):81–6. doi: 10.1007/s00280-002-0533-4.
  54. Quintas-Cardama A, Verstovsek S. Spleen deflation and beyond: The pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms. Cancer. 2012;118(4):870–7. doi: 10.1002/cncr.26359.
  55. Santos FP.S, Verstovsek S. JAK2 Inhibitors: Are They the Solution? Clin Lymph Myel Leuk. 2011;11(Suppl 1):S28–S36. doi: 10.1016/j.clml.2011.02.007.
  56. Tibes R, Mesa RA. Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy? Leuk Lymphoma. 2011;52(7):1178–87. doi: 10.3109/10428194.2011.566952.
  57. Verstovsek S, Passamonti F, Rambaldi A, et al. Durable Responses with the JAK1/JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU). Blood (ASH Annual Meeting Abstracts). 2010;116(21):313.
  58. Moliterno AR, Roboz GJ, Carroll M, et al. An Open-Label Study of CEP-701 in Patients with JAK2 V617F-Positive Polycythemia Vera and Essential Thrombocytosis. Blood (ASH Annual Meeting Abstracts). 2008;112(11):99.
  59. Baerlocher GM, Leibundgut EO, Ayran C, et al. Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results. Blood (ASH Annual Meeting Abstracts). 2012;120(21):179.
  60. Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113(20):4829–33. doi: 10.1182/blood-2008-09-176818.
  61. Schmitt-Graeff A. Standardization of Bone Marrow Biopsy Reporting in Ph-CMPD. LeukemiaNet. 2013; WP9.6:1.
  62. Wolanskyj AP, Schwager SM, McClure RF, et al. Essential Thrombocythemia Beyond the First Decade: Life Expectancy, Long-term Complication Rates, and Prognostic Factors. Mayo Clin Proceed. 2006;81(2):159–66. doi: 10.4065/81.2.159.
  63. Cervantes F, Alvarez-Larran A, Talarn C, et al. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol. 2002;118(3):786–90. doi: 10.1046/j.1365-2141.2002.03688.x.
  64. Verstovsek S, Mesa RA, Gotlib J, et al. Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I. Blood (ASH Annual Meeting Abstracts). 2011;118(21):278.
  65. Harrison CN, Kiladijan JJ, Al-Ali HK, et al. Results of a randomized study of the JAK inhibitor INC424 compared with best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF). J Clin Oncol (ASCO Meeting Abstracts). 2011;29:LBA6501.
  66. Struve S, Finazzi G, Doehner K, et al. Pregnancies in Patients with Philadelphia Negative Chronic Myeloproliferative Disorders: Interim Report of the European LeukemiaNet Data Base. Blood (ASH Annual Meeting Abstracts). 2008;112(11):2806.
  67. Passamonti F, Randi ML, Rumi E, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood. 2007;110(2):485–9. doi: 10.1182/blood-2007-01-071068.
  68. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. J Clin Oncol. 2011;29(6):761–70. doi: 10.1200/jco.2010.31.8436.
  69. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. The Lancet. 2007;369(9575):1791–8. doi: 10.1016/s0140-6736(07)60712-0.
  70. Bangerter M, Guthner C, Beneke H, et al. Pregnancy in essential thrombocythaemia: treatment and outcome of 17 pregnancies. Eur J Haematol. 2000;65(3):165–9. doi: 10.1034/j.1600-0609.2000.90214.x.
  71. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106(2):401–7. doi: 10.1182/blood-2005-02-0626.
  72. Hunt BJ, Gattens M, Khamashta M, et al. Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event. Blood Coagul Fibrinol 2003;14(8):735–9. doi: 10.1097/00001721-200312000-00007.
  73. Gris J-C, Mercier E, Quere I, et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood. 2004;103(10):3695–9. doi: 10.1182/blood-2003-12-4250.
  74. Liebelt EL, Balk SJ, Faber W, et al. NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of hydroxyurea. Birth Defects Research Part B. Devel Reprod Toxicol. 2007;80(4):259–366. doi: 10.1002/bdrb.20123.
  75. Fenaux P, Simon M, Caulier MT, et al. Clinical course of essential thrombocythemia in 147 cases. Cancer. 1990;66(3):549–56. doi: 10.1002/1097-0142(19900801)66:3<549::aid-cncr2820660324>;2-6.